A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

• Status: Unknown status
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Collaborator: LinkDoc Technology (Beijing) Co. Ltd.
• Treatments: Antibodies; Immunoglobulins

Criteria

Inclusion Criteria:

• Pathologically or cytologically confirmed advanced solid tumors;

• Received anti-PD-1/PD-L1 antibody therapy.

Exclusion Criteria:

• No specific exclusion criteria in this real world study.